Biochemistry · 2009 · 108 citations · 56 references
Life SciencesMolecular BiologyOncologyCarcinogenesisGene ExpressionMolecular OncologyHelicase FunctionMrna StabilityPost-translational RegulationRna-binding ProteinsRna-protein InteractionsTranslational RegulationDead-box Rna HelicasesMalignant Breast TumorsProteasomal TurnoverSumoylation Site Prediction
The p68 (DDX5) and p72 (DDX17) proteins are members of the DEAD-box (DDX) family of RNA helicases. We show that both p68 and p72 are overexpressed in breast tumors. Bioinformatical analysis revealed that the SUMO pathway is upregulated in breast tumors and that both p68 and p72 contain one consensus sumoylation site, implicating that sumoylation of p68 and p72 increases during breast tumorigenesis and potentially contributes to their overexpression. We determined that p68 and p72 are indeed sumoylated at a single, homologous site. Importantly, sumoylation significantly increased the stability of p68 and p72. In contrast to p72 and consistent with an approximately 3-fold lesser half-life, p68 was found to be polyubiquitylated, and mutation of the sumoylation site increased polyubiquitylation, suggesting that sumoylation increases p68 half-life by reducing proteasomal degradation. Moreover, whereas p68 robustly coactivated transcription from an estrogen response element, its sumoylation mutant showed a drastically reduced coactivation potential. In contrast, the p68 sumoylation status did not affect the ability to enhance p53-mediated MDM2 transcription. On the contrary, preventing sumoylation of p72 caused an increase in its ability to transactivate both estrogen receptor and p53. Furthermore, sumoylation promoted the interaction of p68 and p72 with histone deacetylase 1 but had no effect on binding to histone deacetylases 2 and 3, the coactivator p300, or estrogen receptor and also did not affect homo/heterodimerization of p68/p72. In conclusion, sumoylation exerts pleiotropic effects on p68/p72, which may have important implications in breast cancer by modulating estrogen receptor and p53 activity.
56
Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 Sites
Kolja Paech, Paul Webb, George G. J. M. Kuiper et al. · Science · 1997 · 1.9K citations
X chromosomal abnormalities in basal-like human breast cancer
Andrea L. Richardson, Zhigang C. Wang, Arcangela De Nicolo et al. · Cancer Cell · 2006 · 885 citations · Full text
Life Sciences, Genetics, Oncology +14
SUMO‐1 modification activates the transcriptional response of p53
Manuel S. Rodríguez, Joana Desterro, Carol Midgley et al. · The EMBO Journal · 1999 · 634 citations
Activation of p53 by conjugation to the ubiquitin‐like protein SUMO‐1
Monica Gostissa, Arnd Hengstermann, Valentina Fogal et al. · The EMBO Journal · 1999 · 509 citations